Rivaroxaban (Xarelto) yl)ethane-1 2-diamine hydrochloride Smiles: C[C@H](N[C@@H](CC1C=CC(=CC=1)C1=CC(Cl)=CC=C1)C(O)=O)C(=O)OCC

Smiles: C[C@H](N[C@@H](CC1C=CC(=CC=1)C1=CC(Cl)=CC=C1)C(O)=O)C(=O)OCC

c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun

Smiles: COC1C=C(NC2=NC3=CC=CC=C3N=C2NS(=O)(=O)C2C=C(C=CC=2)NC(=O)C(C)(C)N)C(Cl)=CC=1

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

APTO-253 is also an inducer of KLF4 (Krüppel-like factor 4)

Rivaroxaban (Xarelto) yl)ethane-1 2-diamine hydrochloride Smiles: C[C@H](N[C@@H](CC1C=CC(=CC=1)C1=CC(Cl)=CC=C1)C(O)=O)C(=O)OCCRivaroxaban, also known as BAY 59 7939, is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 812 hours, but